Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Screening for hypertrophic cardiomyopathy.

Literature DB >> 8461717

Screening for hypertrophic cardiomyopathy.

A L Clark, A J Coats.

Abstract

Entities: Disease

Mesh：

Year: 1993 PMID： 8461717 PMCID： PMC1676509 DOI： 10.1136/bmj.306.6875.409

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

16 in total

1. Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis.

Authors: C E Clark; W L Henry; S E Epstein
Journal: N Engl J Med Date: 1973-10-04 Impact factor: 91.245

2. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.

Authors: W J McKenna; C M Oakley; D M Krikler; J F Goodwin
Journal: Br Heart J Date: 1985-04

3. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

Authors: H Watkins; A Rosenzweig; D S Hwang; T Levi; W McKenna; C E Seidman; J G Seidman
Journal: N Engl J Med Date: 1992-04-23 Impact factor: 91.245

4. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features.

Authors: W McKenna; J Deanfield; A Faruqui; D England; C Oakley; J Goodwin
Journal: Am J Cardiol Date: 1981-03 Impact factor: 2.778

5. Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy.

Authors: J F Lewis; P Spirito; A Pelliccia; B J Maron
Journal: Br Heart J Date: 1992-09

6. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes.

Authors: A Rosenzweig; H Watkins; D S Hwang; M Miri; W McKenna; T A Traill; J G Seidman; C E Seidman
Journal: N Engl J Med Date: 1991-12-19 Impact factor: 91.245

7. Sudden death in young athletes.

Authors: B J Maron; W C Roberts; H A McAllister; D R Rosing; S E Epstein
Journal: Circulation Date: 1980-08 Impact factor: 29.690

8. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.

Authors: L Fananapazir; M B Leon; R O Bonow; C M Tracy; R O Cannon; S E Epstein
Journal: Am J Cardiol Date: 1991-01-15 Impact factor: 2.778

9. Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy.

Authors: N D Epstein; L Fananapazir; H J Lin; J Mulvihill; R White; J M Lalouel; R P Lifton; A W Nienhuis; M Leppert
Journal: Circulation Date: 1992-02 Impact factor: 29.690

10. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings.

Authors: L Fananapazir; A C Chang; S E Epstein; D McAreavey
Journal: Circulation Date: 1992-09 Impact factor: 29.690

10 in total

Screening for hypertrophic cardiomyopathy.

1. Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis.

2. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.

3. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

4. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features.

5. Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy.

6. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes.

7. Sudden death in young athletes.

8. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.

9. Evidence of genetic heterogeneity in five kindreds with familial hypertrophic cardiomyopathy.

10. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings.

1. Covert video surveillance: an important investigative tool or a breach of trust?

2. Cardiac causes for syncope or sudden death in childhood.

3. Genetic testing for familial hypertrophic cardiomyopathy in newborn infants.

4. Plasma concentrations of brain natriuretic peptide: will this new test reduce the need for cardiac investigations?

5. Screening for hypertrophic cardiomyopathy.

6. Costs of screening are important.

7. Heart disease screening in Japanese children.

8. Screening for hypertrophic cardiomyopathy.

9. Genetic investigation and counselling of families with hypertrophic cardiomyopathy.

10. Sudden death in children and adolescents.